BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cabozantinib: Interim Phase II data

Updated interim data from 100 evaluable patients in the cohort of subjects with metastatic castration-resistant prostate cancer (CRPC) in the lead-in stage of an ongoing, adaptive, international Phase II trial showed that oral cabozantinib produced 6 confirmed partial responses, plus 82 cases of stable disease, at a median-follow-up of 3.8 months. The 12-week disease control rate (DCR) was 74%. In the lead-in stage of the study, patients receive once-daily 100 mg cabozantinib for 12 weeks. Patients who achieve a partial response continue open-label cabozantinib, patients with progressive disease discontinue treatment and patients with stable disease enter the randomized discontinuation placebo-controlled study....

Read the full 482 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >